Demand for hospital resources are likely to increase by the end of January 2021 – with a distinctly sharper rate of increase for hospital beds relative to ICU ventilators and other equipment needed for critically ill COVID-19 patients.
This suggests that while cases are rising, the ratio of critically ill cases to total cases will be lower than in the initial surge seen in the early parts of 2020.
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more
